Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN – Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 262,537 shares, a growth of 34.0% from the December 15th total of 195,948 shares. Based on an average daily volume of 149,033 shares, the short-interest ratio is currently 1.8 days. Based on an average daily volume of 149,033 shares, the short-interest ratio is currently 1.8 days.
Inspira Technologies OXY B.H.N. Stock Down 1.5%
Inspira Technologies OXY B.H.N. stock traded down $0.01 during midday trading on Monday, reaching $0.88. 142,520 shares of the company traded hands, compared to its average volume of 168,483. The company has a quick ratio of 0.90, a current ratio of 1.15 and a debt-to-equity ratio of 0.27. Inspira Technologies OXY B.H.N. has a 12 month low of $0.40 and a 12 month high of $1.65. The business has a 50 day moving average of $1.00 and a two-hundred day moving average of $1.13.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Inspira Technologies OXY B.H.N. stock. Citadel Advisors LLC acquired a new position in Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 82,567 shares of the company’s stock, valued at approximately $105,000. Citadel Advisors LLC owned about 0.65% of Inspira Technologies OXY B.H.N. at the end of the most recent quarter. 12.72% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Get Our Latest Research Report on Inspira Technologies OXY B.H.N.
Inspira Technologies OXY B.H.N. Company Profile
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.
Recommended Stories
- Five stocks we like better than Inspira Technologies OXY B.H.N.
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
Receive News & Ratings for Inspira Technologies OXY B.H.N. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspira Technologies OXY B.H.N. and related companies with MarketBeat.com's FREE daily email newsletter.
